Primecap Management Co. CA Buys New Holdings in Mural Oncology plc (NASDAQ:MURA)

Primecap Management Co. CA purchased a new position in shares of Mural Oncology plc (NASDAQ:MURA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 235,551 shares of the company’s stock, valued at approximately $740,000. Primecap Management Co. CA owned approximately 1.39% of Mural Oncology at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. BBR Partners LLC bought a new position in shares of Mural Oncology during the 2nd quarter worth about $31,000. Rhumbline Advisers bought a new position in Mural Oncology during the second quarter worth about $34,000. Dimensional Fund Advisors LP acquired a new stake in Mural Oncology during the second quarter valued at approximately $71,000. Harbor Capital Advisors Inc. bought a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $115,000. Finally, Nicollet Investment Management Inc. acquired a new position in shares of Mural Oncology in the 2nd quarter worth approximately $308,000. Institutional investors own 80.21% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Rodman & Renshaw began coverage on Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 price target on the stock.

Mural Oncology Trading Up 3.3 %

Shares of Mural Oncology stock opened at $3.45 on Thursday. Mural Oncology plc has a 12-month low of $2.88 and a 12-month high of $17.00. The company has a 50-day simple moving average of $3.30 and a 200 day simple moving average of $3.68.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. On average, analysts predict that Mural Oncology plc will post -7.54 EPS for the current year.

Insider Activity at Mural Oncology

In other Mural Oncology news, CEO Caroline Loew sold 12,531 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $2.91, for a total value of $36,465.21. Following the transaction, the chief executive officer now owns 240,391 shares of the company’s stock, valued at $699,537.81. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.